Stake logo

PYXS

PYXIS ONCOLOGY, INC.

About PYXS

Pyxis Oncology, Inc. is an oncology company. The Company is focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. The Company leverages its fully integrated research, development, and commercial capabilities to build a diversified portfolio of next-generation therapeutics. The Company's therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The Company has developed a broad portfolio of novel antibody-drug conjugate (ADC), immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. The Company's product pipelines are PYX-201 and PYX-106.

Buy US stocks in Australia starting with PYXS. Open an account and start investing today!

Market Capitalisation

$56.51M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

15.47K

High today

$1.67

Low today

$1.59

Open price

$1.64

52-week high

$9.49

52-week low

$1.10


PYXS FAQs

One share of PYXIS ONCOLOGY, INC. is valued at $1.65.

The ticker symbol for PYXIS ONCOLOGY, INC. is PYXS.

To buy PYXS stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in PYXS

As of 06/02/2023 PYXIS ONCOLOGY, INC. has a market cap of $57M.

The PYXIS ONCOLOGY, INC. 52-week high stock price is $9.49.

The PYXIS ONCOLOGY, INC. 52-week low stock price is $1.10.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.